RASGRF2 (Ras protein specific guanine nucleotide releasing factor 2) functions as a calcium-regulated nucleotide exchange factor that activates both Ras and RAC1 through GDP-to-GTP exchange, with preferential activation of HRAS in vivo [UniProt]. The protein plays important roles in cellular signaling pathways, particularly in cancer progression where it promotes migration and invasion of colorectal cancer cells by modulating MMP9 expression through Src/Akt/NF-κB signaling 1. RASGRF2 demonstrates complex roles in tumorigenesis, functioning as both a tumor suppressor and oncogene depending on context. In lung cancer, aberrant methylation of RASGRF2 occurs in 34% of non-small cell lung cancer cases, leading to gene silencing 2. Conversely, oncogenic RASGRF2 fusions have been identified in multiple tumor types, including lung adenocarcinoma, where they activate RAS signaling and show sensitivity to MAPK pathway inhibition 34. The gene also influences lymphomagenesis, as RASGRF2 deficiency synergizes with Vav1 loss to promote T-cell lymphoma development 5. Additionally, genetic variants in RASGRF2 serve as prognostic biomarkers for HBV-related hepatocellular carcinoma survival 6, and the protein regulates cell motility through RAC-mediated membrane protrusion formation 7.